Previous 10 | Next 10 |
MELBOURNE, Australia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic me...
MELBOURNE, Australia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet med...
Highlights: Highly experienced pharmaceutical executive with 20+ years at Pfizer and 10+ years at Novo Nordisk Secured FDA registration and marketing approval for 12 significant new drugs in the past 10 years at Novo Nordisk in his capacity of Vice President – US Regu...
Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A PR Newswire Highlights: Incannex have engaged Curia to scale up cGMP fill-finish manufacture of IHL-216A Engagement of Curia follows achievement of "proof-of-concept" formulation development ...
Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement PR Newswire MELBOURNE, Australia , July 27, 2022 /PRNewswire/ -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), ...
Incannex Healthcare ( NASDAQ: IXHL ) is trading 9.3% higher after the company said it had received approval from Australia's Bellberry Human Research Ethics Committee for a phase 1 trial testing its anti-inflammatory drug IHL-675A. The company's drug is a comb...
Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A PR Newswire Highlights: Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of ...
Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference PR Newswire MELBOURNE, Australia , June 27, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL ), ('Incannex' or the 'Company') a clinical-stage ph...
Australia-based developer of medicinal cannabinoids Incannex Healthcare (NASDAQ:IXHL) has added ~20% in the pre-market Friday after the company announced favorable results from a Phase 2 proof-of-concept clinical trial for IHL-42X, an experimental drug for obstructive sleep apnoea. ...
Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea PR Newswire Highlights: IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses ...
News, Short Squeeze, Breakout and More Instantly...
Incannex Healthcare Limited Company Name:
IXHL Stock Symbol:
NASDAQ Market:
Incannex Healthcare Limited Website:
NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is ple...
Incannex Healthcare Inc. (IXHL) is expected to report for Q3 2024
MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investig...